STAAR Surgical (NASDAQ:STAA) Receives Consensus Recommendation of “Hold” from Analysts

Shares of STAAR Surgical (NASDAQ:STAA) have been given an average rating of “Hold” by the eight analysts that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $45.57.

STAA has been the topic of a number of research reports. Morgan Stanley lowered STAAR Surgical from an “equal weight” rating to an “underweight” rating and decreased their price objective for the company from $50.00 to $37.00 in a report on Monday, July 15th. Canaccord Genuity Group decreased their price objective on STAAR Surgical from $43.00 to $41.00 and set a “hold” rating on the stock in a report on Thursday, August 8th. BTIG Research increased their target price on STAAR Surgical from $46.00 to $53.00 and gave the stock a “buy” rating in a report on Monday, July 15th. Stifel Nicolaus reduced their target price on STAAR Surgical from $50.00 to $44.00 and set a “buy” rating on the stock in a report on Monday, August 26th. Finally, Needham & Company LLC reissued a “hold” rating on shares of STAAR Surgical in a report on Thursday, September 19th.

STAAR Surgical Trading Down 0.9 %

STAA opened at $30.42 on Wednesday. The stock’s fifty day simple moving average is $32.95 and its 200 day simple moving average is $39.67. STAAR Surgical has a 1-year low of $26.66 and a 1-year high of $52.68. The stock has a market cap of $1.49 billion, a PE ratio of 98.13 and a beta of 0.59.

STAAR Surgical (NASDAQ:STAA) last issued its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported $0.15 EPS for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.09). STAAR Surgical had a net margin of 4.99% and a return on equity of 5.60%. The firm had revenue of $99.01 million during the quarter, compared to analyst estimates of $95.22 million. During the same period in the prior year, the company earned $0.23 earnings per share. The business’s quarterly revenue was up 7.3% compared to the same quarter last year. Equities analysts forecast that STAAR Surgical will post 0.16 earnings per share for the current year.

Insider Activity at STAAR Surgical

In other STAAR Surgical news, Director Arthur C. Butcher acquired 1,315 shares of STAAR Surgical stock in a transaction that occurred on Monday, August 12th. The shares were acquired at an average cost of $37.99 per share, with a total value of $49,956.85. Following the completion of the purchase, the director now directly owns 4,208 shares of the company’s stock, valued at $159,861.92. This represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.00% of the stock is currently owned by insiders.

Institutional Trading of STAAR Surgical

Several large investors have recently bought and sold shares of the business. Susquehanna Fundamental Investments LLC bought a new position in STAAR Surgical in the first quarter valued at about $2,731,000. Mutual of America Capital Management LLC raised its position in STAAR Surgical by 214.7% in the second quarter. Mutual of America Capital Management LLC now owns 26,459 shares of the medical instruments supplier’s stock valued at $1,260,000 after purchasing an additional 18,051 shares during the last quarter. Russell Investments Group Ltd. raised its position in STAAR Surgical by 1.5% in the first quarter. Russell Investments Group Ltd. now owns 36,931 shares of the medical instruments supplier’s stock valued at $1,406,000 after purchasing an additional 555 shares during the last quarter. Algert Global LLC raised its position in STAAR Surgical by 13.5% in the second quarter. Algert Global LLC now owns 116,655 shares of the medical instruments supplier’s stock valued at $5,554,000 after purchasing an additional 13,901 shares during the last quarter. Finally, ClariVest Asset Management LLC bought a new position in STAAR Surgical in the second quarter valued at about $1,223,000. 96.70% of the stock is owned by institutional investors and hedge funds.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.